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Abstract
The p53 family activates many of the same genes in response to DNA damage. Because p63 and p73 have structural
differences from p53 and play distinct biological functions in development and metastasis, it is likely that they activate a
unique transcriptional network. Therefore, we performed a genome-wide analysis using cells lacking the p53 family
members after treatment with DNA damage. We identified over 100 genes involved in multiple pathways that were
uniquely regulated by p63 or p73, and not p53. Further validation indicated that BRCA2, Rad51, and mre11 are direct
transcriptional targets of p63 and p73. Additionally, cells deficient for p63 and p73 are impaired in DNA repair and p63+/2;
p73+/2 mice develop mammary tumors suggesting a novel mechanism whereby p63 and p73 suppress tumorigenesis.
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Introduction
p53 acts as a tumor suppressor gene by transcriptionally
regulating a multitude of target genes in response to DNA damage
[1]. Induction of these genes results in multiple cellular fates
including apoptosis and cell cycle arrest. p63 and p73 share some
of the same functions as p53; however, p63 and p73 are structurally
more complex containing multiple isoforms [2,3,4]. The TA
isoforms are structurally more like p53 and contain a transactiva-
tion domain while the DN isoforms lack this domain and are
transcribed from an internal promoter unique to these isoforms
[3,5]. Based on the fact that the TA isoforms are more similar
structurally to p53, the TA isoforms were hypothesized and shown
to be the major isoforms that induce transcription and are thought
to have tumor suppressive functions [3,5,6,7,8]. In contrast, the
DN isoforms have been shown to act as dominant negatives against
the TA isoforms of p63 and p73 and also against p53. Because of
the ability of the DN isoforms to act as dominant negatives and
their overexpression patterns in human tumors [2,6,9,10,11], these
isoforms have been hypothesized to act as oncogenes [3,5,6].
Interestingly, recent data have revealed that the DN isoforms of
p73 can induce apoptosis, cell cycle arrest and transactivate target
genes, such as p21, 14-3-3s, and GADD45 [12]. Additional studies
have demonstrated that expression of DNp73b at physiological
levels can result in the suppression of cell growth in the presence or
absence of p53 indicating that this isoform of p73 may act as a
tumor suppressor gene [12]. Similarly, the DN isoforms of p63
have also been shown to have the ability to transactivate target
genes [13]. In the case of p63, the DN isoforms are more highly
expressed in epithelial tissues [14], and thus it is not be surprising
that the DN isoforms transcriptionally regulate genes involved in
the morphogenesis and differentiation of the epithelium. Given the
structural complexity and expression of p63, p73, and their
isoforms, the transcriptional targets of these genes are an area of
growing research.
We and others have shown previously that p63 and p73 can
induce apoptosis in response to DNA damage [2,8,15]. Many of
the target genes induced by p63 and p73 are shared with p53 [2,8].
Additionally, we have shown that the p53 family of genes is
interdependent on each other in the apoptotic response and in the
suppression of tumorigenesis. p53+/2;p63+/2 and p53+/2;
p73+/2 develop some of the same tumor types as p53+/2 mice,
but the phenotype of the tumors in the compound mutant mice
is highly aggressive and metastatic indicative of cooperativity
between family members [7,15]. Mice heterozygous for combina-
tions of the p53 family members develop a novel tumor spectrum
compared to p53+/2 mice indicative of functions of p63 and p73
independent of p53 [7]. These independent functions suggest that
p63 and p73 may have unique transcriptional programs.
To understand the transcriptional program of p63 and p73, we
made use of MEFs deficient for each of the p53 family members
individually and in combination and performed a genome wide
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and p73 transcriptionally regulate genes independently of p53 in
response to DNA damage. Interestingly, we found that p63 and/or
p73transactivatesetsofgenesindependentofp53.Amongthesesets
of genes are those involved in homologous DNA repair, including
Rad51, BRCA2, mre11 and Rad50. p63 and p73 were found to bind
to these gene promoters by ChIP assay and to transactivate them as
demonstrated by luciferase assay. Surprisingly, the DN isoforms of
p63 and p73, which have been shown to be weak transactivators,
transactivate the Rad51 and BRCA2genesto high levels. In addition,
p632/2, p732/2 and p632/2;p732/2 MEFs exhibited an
impaired ability to repair their DNA and to survive in a clonogenic
survival assay. Additionally, in vivo evidence from p63/p73 mutant
mice supports this finding; p63+/2;p73+/2 mice develop mam-
mary adenocarcinomas at a high frequency [7]. Here, we show that
these mammary tumors lose expression of p63, p73, BRCA2, and
Rad51. Our findings indicate that p63 and p73 may suppress
tumorigenesis by transcriptionally regulating critical genes in the
DNA repair pathway.
Results
The p53 family of genes cooperates and acts
independently in the regulation of transcriptional targets
The p53 family members, p63 and p73, have previously been
shown to share many of the same target genes as p53 [2,8].
Additionally, both p63 and p73 have the ability to bind to the p53
consensus binding site. p63 and p73 also have biological activities
independent of p53. Consequently, we were interested in
determining whether p63 and p73 had unique transcriptional
target genes. A cDNA microarray analysis was performed using
E1A expressing MEFs deficient for each p53 family member
individually (p532/2, p632/2, p732/2) and in combination
(p632/2;p732/2). These cells were treated with doxorubicin, a
DNA damaging agent, to induce apoptosis in wild-type E1A
MEFs. p532/2 and p632/2;p732/2 E1A MEFs have
previously been shown to be resistant to this treatment while the
p632/2 and p732/2 E1A MEFS are partially resistant to
apoptosis [15]. Microarray analysis revealed a large number of
genes differentially expressed in the MEFs deficient for each p53
family member. Because we were interested in identifying genes
that are transactivated by the p53 family members in response to
DNA damage, genes that are down regulated in the absence of the
p53 family members were further analyzed.
After filtering and statistical analysis using SAM [16], 620 out of
15,488 genes were found to be down regulated in at least one of
the single knockout E1A MEF lines compared to wild-type E1A
MEFs in response to DNA damage. Eight-six of the 620 genes
were down regulated in the p532/2, p632/2, and p732/2
E1A MEFs as illustrated by the Venn diagram (Figure 1 and
Figure S1). There were also sets of genes that were uniquely
regulated by each p53 family member; the p532/2, p632/2,
and p732/2 MEFs each had 109, 148, and 131 genes down
regulated respectively. Lastly, there were sets of genes that were
regulated by two family members only; forty-seven were down
regulated in the absence of p53 and p63, 41 in the absence of p53
and p73, and 58 in the absence of p63 and p73. The final list of
differentially regulated genes was processed through multiple
bioinformatic pipelines to identify biological pathways regulated
by the p53 family members. Pathway analysis using the web-based
KEGG, BioCarta, and GenMAPP databases indicated that the
p53 family members regulate numerous pathways including: cell
cycle, DNA-damage, p53 signaling, apoptosis, ribosomal proteins,
metabolic pathways, and growth factor signaling (Table S1).
The putative target genes identified by microarray analysis were
analyzed for the presence of a p53 or p63 consensus binding sites
using a computer based genome wide search and HMMER1
software [17]. The promoter sequences (defined as 5 kb upstream
and downstream of the transcription start site excluding exons)
from the 724 down regulated genes were queried, and 700 of these
genes were found to have p53 family member motifs. Of these, 669
genes contained p53 family member motif sites with the ideal p53
spacer of 6 nucleotides between the two half sites. Scores were then
given to each identified binding site corresponding to how well
they matched with previously published p53 or p63 matrices
(Table S2).
Figure 1. Venn diagram illustrating genes down regulated in
the absence of the p53 family members. Eighty-six genes (brown)
were down regulated in the absence of all three p53 family members. A
number of genes were down regulated in the absence of each p53
family member individually; 109 in p53 deficient cells (red), 148 in p63
deficient cells (yellow), and 131 in p73 deficient cells (blue). Several
genes were down regulated in the absence of two family members; 47
in the absence of p53 and p63 (orange), 58 in the absence of p63 and
p73 (green), and 41 in the absence of p53 and p73 (purple).
doi:10.1371/journal.pgen.1000680.g001
Author Summary
p63 and p73 have been identified as important suppressors
of tumorigenesis and metastasis. Although they are
structurally similar to p53, they have many functions that
are unique including roles in development and metastasis.
Here we show, using a genome-wide analysis of cells
lacking p63 and p73 individually and in combination, that
p63 and p73 regulate many unique target genes involved
in multiple cellular processes. Interestingly, one of these
pathways is DNA repair. Further validation of differentially
expressed target genes in this pathway, revealed that p63
and p73 transcriptionally regulate BRCA2, Rad51, and
mre11 providing a novel mechanism for the action of
p63 and p73 in tumor suppression. These findings have
important therapeutic implications for cancer patients
with alterations in the p63/p73 pathway.
p63 and p73 Regulate DNA Repair after DNA Damage
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out MEFs relative to wild-type after DNA damage to highlight
patternsbetweenthe downregulated genesinthe p532/2,p632/2
and p732/2 E1A MEFs (Figure 2 and Figure S1). Interestingly,
many genes were differentially regulated in the various MEF lines
(Figure 2) indicating that p63 and p73 have unique target genes.
Also, many genes were found to be down-regulated in all mutant cell
types supporting the hypothesis that all three transcription factors
can transactivate some of the same gene targets (Figure 2).
DNA damage triggers numerous cellular responses including an
extensive DNA repair pathway involving numerous genes [18].
Microarray analysis revealed that the p53 family members regulate
numerous genes involved in the DNA repair pathway. Many of
these genes seemed to be uniquely regulated by p63 and/or p73.
After DNA damage, loss of p63 or p73 prevents induction of Brca2
(Figure 2, cluster 4), an essential co-factor in Rad51-dependent
DNA repair of double-stranded breaks, and Rad51 itself (Figure 2,
cluster 3) [18]. Sequence analysis also indicates that p53/p63
response elements exist in both the promoter and intronic region
of Brca2 and Rad51 (Table 1 and Table S2). Clustered with Rad51
are Dbf4, a regulator of Cdc7 and a prognostic determinant for
melanoma development, and Gas6, which cooperates with the
tyrosine receptor kinase Axl in tumor proliferation and cell survival
(Figure 2, cluster 3). We also found additional genes that were
uniquely down-regulated in p632/2, p732/2, and p632/2;
p732/2 MEFs. These hits indicate that p63 and p73 have roles
Figure 2. Heatmap showing unsupervised hierarchical clustering analysis of p53, p63, and p732/2 E1A MEFs after doxorubicin
treatment. Each row represents the specified gene. Each column represents the expression level of a specified knock out MEF line relative to the
expression level of wild-type MEFs after DNA damage. The red color indicates upregulation, the green color indicates down regulation, while black
indicates no significant change of the indicated gene expression. Clustering based on Euclidean distance indicates that p63- and p73-deficient E1A
MEFs are more similar to each other than to p532/2 E1A MEFs. Genes of interest are listed in boxes and are associated with their corresponding
location on the heatmap.
doi:10.1371/journal.pgen.1000680.g002
p63 and p73 Regulate DNA Repair after DNA Damage
PLoS Genetics | www.plosgenetics.org 3 October 2009 | Volume 5 | Issue 10 | e1000680independent of p53 in the DNA-damage response pathway. For
example, expression of Rad50, which forms a complex with mre11
and Nebrin, is found to be down regulated in p632/2;p732/2
MEFs relative to wild-type MEFs treated with doxorubicin. There
are also p53 family response elements upstream of the transcrip-
tion start site of Rad50 (Table S2).
In addition to genes that are uniquely regulated by p63 and/or
p73, genes controlled by all three p53 family members were
identified. Mre11, a gene that functions in the repair of DNA double
strand breaks, was found to be down-regulated in p53, p63,a n dp73
deficient E1A expressing MEFs (Figure 2, cluster 1). In addition,
sequence analysis revealed multiple p53/p63 response elements
(Table S2). Genes with similar expression profiles as mre11 include
the growth factor signaling components Ghr and Sos1 as well as the
apoptotic components Traf1 and Cathepsin D all of which contain p53
family member binding sites (Figure 2, cluster 1 & 6 & Table S2).
Multiple genes involved in other biological processes, including
tumor progression, metastasis and development were found to
be differentially regulated in the various E1A MEF cells. For
example, Mmp2, a gene shown to play a role in embryonic
development and tumor metastasis, is also down regulated in the
absence of p73 after doxorubicin treatment. Clustered with Mmp2
are many signaling components such as Grb2, Stat1, Map3k14, and
Mapk8ip3- all of which have at least one p53 family member
binding motif present near its promoter (Figure 2, cluster 5 and
Table S2). Interestingly, brachyury, the developmental transcription
factor, was identified as a putative p63 target gene (Figure 2,
cluster 2). Given the identified roles of brachyury in limb
development, cancer, and hematopoetic stem cells and the
development phenotype of the p632/2 mouse, this putative
target has important biological significance [19,20,21,22]. We
found brachyury to contain multiple p53 family response elements
both upstream of its transcriptional start site and within the first
intron (Table S2). Other p63 dependent genes that cluster with
brachyury include Abr, the GAP for the small GTPase Rac, Socs3,
involved in cytokine and apoptotic signaling, and the zinc-finger
transcription factor Klf9 which is implicated in control of cell
proliferation, cell differentiation, and cell fate (Figure 2, cluster 2).
Genes involved in DNA repair are not induced in
response to DNA damage in the absence of p63 and/or
p73
Strikingly, the results from the cDNA microarray indicate that
genes in the DNA repair pathway are differentially regulated in
MEFs lacking p63 and/or p73 after treatment with DNA
damaging agents. To verify these putative transcriptional targets
of p63 and p73, quantitative real time PCR was performed. The
expression of mre11, BRCA2, Rad51, and Rad50 was examined in
wild-type, p532/2, p632/2, p732/2 and p632/2;p732/2
E1AMEFsbeforeandaftertreatmentwithdoxorubicinfor12 hours
and 5 Gy of gamma radiation. Interestingly, mre11, BRCA2, Rad51,
and Rad50 are all induced in wild-type E1A MEFs after these
treatments (Figure 3). We measured the baseline levels of mRNA of
mre11, BRCA2, Rad51,a n dRad50 to determine levels of these
transcripts prior to DNA damage (Figure S2). After treatment with
doxorubicin or gamma radiation, levels of mre11 mRNA are not
induced to wild-type levels in p632/2and p632/2;p732/2 E1A
indicatingthatp63maytranscriptionallyregulatethisgene(Figure3).
Similarly, the levels of BRCA2 are significantly lower in p732/2
and p632/2;p732/2 E1A MEFs than in wild-type or p532/2
E1A MEFs (Figure 3) after treatment with doxorubicin and gamma
radiation. Likewise, the Rad51 gene is not induced to wild-type levels
in p632/2, p732/2,a n dp632/2;p732/2 E1A MEFs after
treatment with DNA damaging agents (Figure 3), indicating again
that p63 and p73 may be critical transcriptional activators of Rad51
after DNA damage. Lastly, Rad50 also showed a pattern indicative
of transcriptional regulation by both p63 and p73. The mRNA levels
of Rad50 are approximately 4-fold lower in p632/2;p732/2 E1A
MEFs than in wild-type E1A MEFs (Figure 3) after treatment with
doxorubicin and gamma radiation. Taken together, these data
indicate that mre11, BRCA2, Rad51,a n dRad50 may be transcrip-
tional targets of p63 and p73 in response to DNA damage.
Loss of p63 and p73 in mice results in mammary
adenocarcinomas with low expression of BRCA2 and
Rad51
As previously reported, twenty percent of mice heterozygous for
p63 and p73 (p63+/2;p73+/2) develop mammary adenocarcino-
mas [7] (Figure 4), and ninety percent of these tumors lose the
wild-type allele of p63 and p73 [7]. Given that BRCA2 plays an
important role in the pathogenesis of mammary adenocarcinoma,
this made it a relevant biological target for p63 and p73 in
mammary tumors. The protein levels of Rad51 was first examined
by Western blot analysis using wild-type and p632/2;p732/2
MEFs. Interestingly, the basal level of Rad51 is lower in p632/2;
p732/2 MEFs compared to wild-type MEFs (Figure 4A). The
levels of Rad51 in p632/2;p732/2 MEFs are not induced in
response to gamma irradiation; however, a 2-fold increase in
Table 1. p53 family response elements assayed by ChIP.
Element Intron Sequence MM/spacer Binding
RAD51-1 1 : 21766 atgCTTGcca acaCTTGatt 4/0 none
RAD51-2 1 : 2220 ctcCTAGaac tgaagttataa acaCATGaat 8/11 p73
RAD51-3 2 : +867 aaaCAAGcca c aaaCAAGtag 3/1 p73
RAD51-4 2 : +1347 gagCTTGgtg gcaCTTGctt 3/0 none
BRCA2 2 : +133 agtCAAGgtg aa tgCTTGctt 4/1 p63 & p73
MRE11-1 1 : 2744 tggCTTGtgg cctccctggtcgactc tgaCAAGtcc 4/16 none
MRE11-2 1 : 2712 gtcCATGttg ggtaacttaggctttgctac ggtCTTGtag 6/20 none
MRE11-3 1 : 2171 gcgCTTGttc aaaaagtctaccctgcaactga gctCATGtta 4/22 p63
Shown are the sequence elements assayed by ChIP analysis. Mismatches are shown in bold-face type.
The intron number and location are shown for each element. MM denotes the number of mismatches to the p53/p63 consensus binding site, spacer indicates the
number of nucleotides within the spacer region of the putative binding site, and the binding column shows which family member bound to the element by ChIP assay.
doi:10.1371/journal.pgen.1000680.t001
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DNA damage. To determine whether this change in expression
pattern of Rad51 was cell-type specific, we performed immuno-
histochemistry on mammary adenocarcinomas from p63+/2;
p73+/2 mice where LOH of p63 and p73 had occurred (n=10)
(Figure 4F–4I). Indeed, Rad51 as well as BRCA expression is
detected in normal mammary glands (n=10) of p63+/2;p73+/2
mice (Figure 4B and 4D) and is lost in hyperplastic mammary
glands (n=4) and mammary adenocarcinomas (n=6) in these
mice (Figure 4C and 4E).
p63 and p73 bind to the promoter regions of Rad51,
BRCA2, and mre11
Both the cDNA microarray and real-time RT-PCR data
provide evidence that BRCA2, Rad51, and mre11 are transcrip-
tionally regulated by p63 and p73 after DNA damage (Figure 3).
Consequently, chromatin immunoprecipitation (ChIP) assay was
performed to determine whether p63 and/or p73 could directly
bind to the promoter region of these two genes. A subset of
putative binding sites identified and summarized in Table 1 were
assayed using ChIP. Sites chosen included those with the best
scores for p53 and p63. Four putative binding sites were assayed
for RAD51 (Table 1). RAD51-1 and 2 are located in intron 1,
upstream of the start site, while RAD51-3 and 4 are found in
intron 2, downstream of the start site. One putative element was
assayed for BRCA2 in intron 2, 133 nucleotides downstream of the
start site (Table 1). Lastly, three putative p53 family response
elements were queried for mre11: MRE11-1, 2, and 3, located in
intron 1, upstream of the start site (Table 1).
ChIP analysis was performed using an antibody for p53, p63 or
p73 in wild-type, p532/2, p632/2, and p732/2 E1A MEFs
treated with doxorubicin for 12 hours (Figure 5). Interestingly, p73
was the only p53 family member that binds to the RAD51
promoter after DNA damage treatment. p73 was found to bind to
RAD51-2 and 3 in intron 1 and intron 2 respectively. The primers
used for this PCR reaction did not distinguish between the two
sites; therefore, it is possible that p73 only binds to one of these
sites. p63 and p73, but not p53, were found to bind to the response
element in BRCA2 after DNA damage (Figure 5). Lastly, p63 was
the only family member found bound to the mre-11 promoter at
site mre11-3 within intron 1, 171 nucleotides upstream of the start
site. The same binding pattern in the ChIP assay was obtained
with other DNA damaging agents, such as gamma radiation (data
not shown).
DNp63 and DNp73 transactivate Rad51, BRCA2, and
mre11 promoters
The ChIP results clearly demonstrate that p63 and/or p73 can
bind to the promoters of these genes; however to gain a clear
indication of which isoforms of p63 and p73 transactivate Rad51,
BRCA2,a n dmre11, luciferase assays were performed with TA and
DN isoforms of p63 and p73. Regions shown to bind by ChIP assay
were used to construct firefly luciferase reporters. pGL3-Rad51-1
was designed by cloning intron 1 containing RAD-51-1 and 2
(Table1)into thepGL3basicvector and pGL3-Rad51-2 containing
the elements, RAD51-3 and 4, was cloned in to the pGL3 basic
vector. These constructs were transfected in to p632/2;p732/2
MEFs along with a renilla luciferase gene and one of the following
isoforms of p63 or p73:T A p 6 3 a,T A p 6 3 c,T A p 7 3 a,T A p 7 3 b,
DNp63c, DNp73a,a n dDNp73b. Interestingly, both DNp63a and
DNp73b are the isoforms that transactivate the Rad51 reporter gene
to appreciable levels. DNp63a transactivates pGL3-Rad51-1 11 fold
and DNp73b transactivates this reporter 6 fold (Figure 6A). These
isoforms more modestly transactivate the pGL3-Rad51-2 reporter
indicating that the p63/p73 element resides in intron 1 (Figure 6A
and 6B). Surprisingly, the TA isoforms did not transactivate the
reporter gene. The p63/p73 family members also transactivate this
reporter gene. DNp63a and DNp73b together can transactivate the
Rad51-1reporter 19 fold(Figure 6A and 6B). Additionally,the other
DN isoforms that modestly transactivate this reporter alone can
transactivate this reporter to higher levels. For example, DNp63a
along with DNp73a can transactivate this reporter gene 9.8 fold,
demonstrating additive effects between these family members.
Similar to the experiments for RAD51, the BRCA2 region
within intron 1 found to be bound by both p63 and p73 was
cloned in to the pGL3 basic vector. Dual-luciferase reporter assay
was performed in p632/2;p732/2 MEFs as described above.
Strikingly, the isoform with the highest ability to transactivate this
Figure 3. Genes involved in DNA repair are differentially expressed in MEFs deficient for p63 and/or p73. Real time PCR analysis of E1A
MEFs of the following genotypes (wild-type, p532/2, p632/2, p732/2 and p632/2;p732/2) after treatment with (A) doxorubicin (0.34 mM) for
12 hours or (B) c radiation (12 hours). The Y-axis shows the fold induction. Bars represent 3 MEF lines for each genotype, each performed in triplicate.
Data represent the mean 6 SEM. The asterisk denotes statistical significance compared to wild-type, p,0.001.
doi:10.1371/journal.pgen.1000680.g003
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DNp63a and DNp73b can transactivate the reporter 6 fold and
other combinations of DN isoforms also show increases in
transactivation of this reporter (Figure 6C).
The ability of p63 and p73 to transactivate the mre11 gene was
also tested by luciferase assay. The region shown to bind to p63 by
ChIP analysis was cloned in to the pGL3 basic vector to generate
pGL3-Mre11. This reporter was induced 3.8 fold by DNp63a and
DNp73b together (Figure 6D). pPERP-luc, which has previously
been shown to be responsive to TAp63c was used as a positive
control for these experiments [23,24].
To determine whether p53 could transactivate these reporters,
p53 was transfected with each reporter and luciferase activity was
measured. p53 did not induce any of the reporters assayed
(Figure 6A–6D).In addition, we performed luciferase assays using the
Rad51-1 and BRCA2 reporters in MEFs lacking p53, p532/2;
p732/2 (Figure 6E and 6F) and p532/2;p632/2 (data not
shown). These experiments yielded similar results as those shown in
Figure 6A and 6C. Taken together, these data indicate that the
trasactivation of Rad51, BRCA2,a n dmre11 is p53-independent.
Loss of p63 and p73 impairs DNA repair
Rad51 and BRCA2 are both involved in homologous recombi-
nation (HR) DNA repair, one of the major pathways for repair of
double strand breaks (DSBs). Cells lacking genes involved in HR,
like BRCA2 and Rad51, have been shown to have an impaired
ability to repair their DNA [18,25,26,27]. Consequently, we
hypothesized that cells lacking p63 and/or p73, which have low
levels of these two proteins, may have a defect in repairing DSBs in
damaged DNA. To test this hypothesis, wild-type, p532/2,
p632/2, p732/2, and p632/2;p732/2 primary and E1A
MEFs were treated with 5 Gy gamma-radiation or doxorubicin to
generate DSBs. A comet assay was then performed to determine
the DSB repair capacity in these cells. Comet assay, or single cell
gel electrophoresis, is a commonly applied approach for detecting
DNA damage in a single cell. The unwound, relaxed DNA
migrates out of the cell during electrophoresis and forms a ‘‘tail’’
[28]. Therefore, cells that have damaged DNA appear as comets
with tails containing fragmented and nicked DNA, while normal
cells do not. The degree of DNA damage is represented using the
parameter known as tail moment defined as the product of the tail
length and the portion of total DNA in the tail. MEFs lacking the
Figure 4. Low expression of BRCA2 and Rad51 in cells and
mammarytumors deficient forp63 and p73. (A) Westernblot analysis
for Rad51 using whole cell lysates from wild-type and p632/2;p732/2
MEFs treated with 0 Gy or 10 min (m), 30 m, 1 hour (h), 2 h and 4 h after
5 Gy of gamma irradiation. Actin was used as a control for equal loading.
(B–I) Immunohistochemistry (IHC) of normal mammary tissue or mammary
adenocarcinomas from p63+/2;p73+/2 mice using antibodies as follows:
(B) normal mammary tissue from p63+/2;p73+/2 mouse using Rad51
antibody, (C) mammary adenocarcinoma from p63+/2;p73+/2 mouse
using Rad51 antibody, (D) normal mammary tissue from p63+/2;p73+/2
mouse using BRCA2 antibody, (E) mammary adenocarcinoma from p63+/2;
p73+/2 mouse using BRCA2 antibody, (F) normal mammary tissue from
p63+/2;p73+/2mouse using p63 antibody, (G) mammary adenocarcinoma
from p63+/2;p73+/2 mouse using p63 antibody, (H) normal mammary
tissue from p63+/2;p73+/2 mouse using p73 antibody, (I) mammary
adenocarcinoma from p63+/2;p73+/2 mouse using p73 antibody.
doi:10.1371/journal.pgen.1000680.g004
Figure 5. p63 and/or p73 bind to intronic regions within genes
involved in DNA repair. Chromatin immunoprecipitation (ChIP)
analysis using wild-type E1A MEFs (WT) and E1A MEFs deficient for the
p53 family members (p532/2, p632/2 and p732/2) before (U) and
after treatment with doxorubicin (D) for 12 hours. Antibodies used to
immunoprecipitate protein-DNA complexes in each cell line are shown
in various colors: p53 (red), p63 (blue), and p73 (green). Total input
chromatin is shown for each sample (input). Each ChIP was performed
using 3 independent MEF lines in triplicate.
doi:10.1371/journal.pgen.1000680.g005
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PLoS Genetics | www.plosgenetics.org 6 October 2009 | Volume 5 | Issue 10 | e1000680Figure 6. DN isoforms of p63 and p73 transactivate Rad51 and BRCA2 luciferase reporter genes. Bar graphs showing fold induction for
each luciferase reporter gene in (A–D) p632/2; p732/2 or (E,F) p532/2;p732/2 primary MEFs. Reporter genes used are as follows: (A,E) pGL3-
Rad51-1 containing the binding elements in intron 1, (B) pGL3-Rad51-2 containing the binding elements in intron 2, (C,F) pGL3-BRCA2 containing the
binding element in intron 2, and (D) pGL3-mre-11 containing the binding element in intron 1. Pluses above each bar graph indicate which isoforms of
p63 or p73 were transfected in cells with the firefly-luciferase reporter genes. Renilla-luciferase was used as a control for transfection efficiency, and
pPERP-luc was used as a positive control. Each experiment was performed 6 times using 3 independent MEF lines. Data are represented as the mean
6 SEM.
doi:10.1371/journal.pgen.1000680.g006
p63 and p73 Regulate DNA Repair after DNA Damage
PLoS Genetics | www.plosgenetics.org 7 October 2009 | Volume 5 | Issue 10 | e1000680p53 family members were treated with DNA damage and
incubated for a total of 16 hours allowing the homologous
recombination repair to take place. Cells were and harvested at
0 (untreated), 1, and 16 hours for the Comet assay. In all cases,
p632/2, p732/2, and p632/2;p732/2 MEFs were found to
have the largest tail moment after DNA damage (Figure 7A–7D).
The tail moment after DNA damage was significantly higher for
p632/2, p732/2, and p632/2;p732/2 primary and E1A
MEFs (18.8) compared wild-type samples (p ,0.0001). This result
indicates that p63 and p73 play a critical role in DNA repair.
Loss of p63 and p73 reduces cell survival
Because loss of p63 and p73 impair DSB repair by regulating
Rad51, BRCA2, and mre11, it is likely that loss of p63 and p73
results in poor cell survival due to the inability to repair damaged
chromosomal DNA. To determine whether loss of p63 and p73
results in a decrease in cell survival, a clonogenic survival assay was
performed using both primary MEFs and E1A expressing MEFs
after treatment with 1, 2 and 3 Gy of gamma radiation and 0.34,
0.5, and 1.0 mM doxorubicin. After 12 hours, cells were replated
and assayed for the ability to form colonies. p632/2;p732/2
E1A MEFs and primary MEFs have an impaired ability to form
colonies after gamma radiation indicative of defects in DNA repair
(Figure 7E and 7F). A similar result was seen after treatment with
doxorubicin in these cells (Figure 7G and 7H).
Discussion
p53 transactivates a vast network of genes in response to DNA
damage [1]. While p63 and p73 can also transactivate known p53
target genes to varying degrees, they play roles in distinct
biological functions including development and metastasis and
likely have unique transcriptional targets. The advantage of the
system employed here is the use of isogenic primary cells with the
deletion of a single p53 family member. Here, we used early
passage MEFs lacking the p53 family members individually or
both p63 and p73 in combination and expressing E1A, which
sensitizes them to undergo apoptosis after DNA damage to identify
changes in gene expression in this process. We identified sets of
genes that are regulated by individual and multiple p53 family
members indicating unique and overlapping functions for this
family of genes in response to DNA damage. Six hundred twenty
out of 15,488 genes queried were regulated by a p53 family
member. Genes identified played a role in multiple processes
including apoptosis and DNA repair. In addition to engaging
pathways predicted to be induced by DNA damage, genes
involved in other processes like development and metastasis were
also induced. These are biologically significant given the reported
developmental, tumor, and metastatic phenotypes of the p63/p73
mutant mice [7,20,22,29]. Lastly, the majority of the targets
identified had binding sites that closely fit the p53 and p63
consensus binding site [14,30,31] indicating that they may be bona
fide direct transcriptional targets of these family members. Indeed,
we verified that Rad51, BRCA2, and mre11, genes involved in DNA
repair, are direct transcriptional targets of p63 and p73.
Given the high prevalence of mammary adenocarcinoma in
mice mutant for p63 and p73 (p63+/2;p73+/2), a group of genes
of interest are those involved in DNA repair. These genes were
induced in wild-type cells and down regulated in the absence of
p63 or p73. The mechanism for the tumor suppressive activity of
p63 and p73 is not completely understood [6,7,32]. Regulation of
DNA repair genes by p63 and p73 has not been demonstrated
previously and could be a pathway employed by these genes in
tumor suppression. Both Rad51 and BRCA2 were found to be
direct transcriptional targets of p63 and p73 indicating that these
mechanisms may be triggered during tumorigenesis. Interestingly,
Rad51 has been shown previously to be repressed by p53 through
a site found upstream of the start site [33]. Here, we show that
DNp63 and DNp73 transactivate Rad51 through a distinct
element in intron 1 indicating that there is an intricate and
complex regulation of this gene by the p53 family and is likely a
critical target in tumor suppression by this family. We also showed
that transcriptional regulation of Rad51, BRCA2, and Rad51 by
p63 and p73 is p53-independent/
It was surprising that the DN isoforms of p63 and p73 were
more potent transactivators of Rad51, BRCA2, and mre11 than the
TA isoforms. The TA isoforms have an acidic N-terminal domain
necessary for transactivation [2,3], and many studies have shown
previously that the TA isoforms are more potent transactivators
than the DN isoforms [2,8]. Furthermore, the DN isoforms are
better known for the dominant negative activities that they impose
on the TA isoforms of p63 and p73 and p53. Interestingly, a
number of recent studies have shown that the DN isoforms are
capable of transactivating target genes due to a proline-rich
transactivation domain that exists in these isoforms [12,13]. In
addition, the DN isoforms of p63 are more highly expressed than
TAp63 in certain tissues including the skin [14] making the
DNp63 isoforms likely candidates for gene regulation in these
tissues. Taken together, our results indicate that the roles of the
DN isoforms are more complex than previously appreciated.
We have shown previously that E1A expressing MEFs deficient
for p63 and p73 are resistant to apoptosis [15]. Paradoxically, we
found that p632/2;p732/2 primary and E1A MEFs are
radiosensitive in long-term clonogenic assays. This finding coupled
with the inability of p63/p73 deficient cells to repair DNA as
shown by Comet assay indicate that p63 and p73 play a critical
role in DNA repair. This new finding does not preclude that p63/
p73 deficient cells are resistant to apoptosis after acute exposure to
DNA damage. These data demonstrate that surviving p632/2;
p732/2 cells are unable to proliferate and establish a colony after
DNA damage. This is likely due to defects in the DNA repair
mechanisms.
Using a genome wide analysis, these studies have revealed novel
transcriptional targets of the p53 family members. We have also
identified a novel mechanism of the regulation of the DNA repair
pathway by p63 and p73. Given the high incidence of mammary
adenocarcinoma in p63/p73 mutant mice, these studies have
unveiled a potential mechanism for p63 and p73 as tumor
suppressor genes. In addition, our studies have revealed further
complexity by indicating that the primary transactivators of these
DNA repair genes are the DN isoforms of p63 and p73. These
isoforms have previously been thought to act as oncogenes. More
recent data have challenged this notion as these isoforms can also
transactivate genes involved in apoptosis and the expression of
these isoforms does not provide a growth advantage [12]. These
studies provide further evidence that the DN isoforms may have
some anti-tumor functions such as the ability to engage DNA
repair pathways. Future studies using isoform specific knock out
mice should yield important insights in to how each of these
isoforms contributes to tumor suppression and shed light on the
interactions of the complex p53 family.
Materials and Methods
Preparation of 15 K murine cDNA microarrays
The Laboratory of Genetics at The National Institute on Aging
(NIA) cloned approximately 15,000 unique cDNAs into the NotI/
SalIsite of Ampicillin-resistant pSPORT1 vector (LifeTechnologies).
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PLoS Genetics | www.plosgenetics.org 8 October 2009 | Volume 5 | Issue 10 | e1000680Figure 7. Cells deficient for p63, p73, or both p63 and p73 have an impaired ability to repair damaged DNA and exhibit increased
sensitivity to ionizing radiation. (A–D) DNA damage (tail moment) detected by the Comet assay at 0 (untreated), 1, and 16 hours in E1A MEFs
treated with (A) 5 Gy c radiation, (B) 0.34 mM doxorubicin or primary MEFs treated with (C) 5 Gy c radiation, and (D) 0.34 mM doxorubicin. Genotypes
are indicated on the x-axis and tail moment is shown on the Y-axis. Three independent MEF lines were assayed for each genotype in triplicate.
Asterisks indicate statistical significance compared to wild-type (p ,0.0001). (E,F) Clonogenic survival of E1A MEFs of the indicated genotypes
following (E) gamma radiation and (F) doxorubicin. (G,H) Clonogenic survival of primary MEFs of the indicated genotypes following (G) gamma
radiation and (H) doxorubicin. Percent (%) survival is indicated on the Y-axis for each dose of gamma-irradiation (0, 1, 2, 3 Gy) or doxorubicin (0.34,
0.5, 1 mM) on the x-axis. Three independent MEF lines were assayed for each genotype in triplicate. Data are represented as the mean 6 SEM.
doi:10.1371/journal.pgen.1000680.g007
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amplified for microarray printing following a modified version of the
protocol described previously [34]. In 96 well format, bacterial stocks
were grown overnightin 2X YT medium (100 mg/mlampicillin)with
agitation. Ten microliters ofthe overnightbacterialculturewas added
to 90 ml ddH2O in PCR plates (MJ Research) and denatured at 95uC
for 10 minutes. Following denaturation, plates were centrifuged for
10 minutes. To perform PCR, 5 ml of supernatant from each well
was used as template in a 100 ml reaction with 3.5 units of AmpliTaq
DNA polymerase (Applied Biosystems), forward primer (59–
CCAGTCACGACGTTGTAAAACGAC-39) reverse primer (59-
GTGTGGAATTGTGAGCGGATAACAA-39), and deoxynucleo-
tide triphosphates (dNTPs). Amplification was carried out in
thermocyclers with a program that contained an initial denaturation
step at 95uC for 2 minutes followed by 38 cycles of 30 s at 94uC, 45 s
at 65uC, and 3 minutes at 72uC, and a final extension of 5 minutes at
72uC.TheamplifiedinsertswerethenpurifiedusingMontagePCR96
cleanup Filter Plates (Millipore) on a BIO-TEK Precision 2000
Automated Microplate Pipetting System to a purified volume of
100 ml. Thirty-five microliters of each purified PCR product was
added to a 384-well plate, and desiccated using a large Savant Speed-
vac apparatus, then reconstituted in 7 ml of 3X SSC/1.5 M betaine
to a mean concentration of 600 ng/ml. The microarrays were
fabricated at the MIT BioMicro Center using Corning GAPS II
GammaAminoPropylSilaneslides.cDNA cloneswereprinted using
a BioRobotics Microgrid 600 TAS Arrayer with a 32-pin print head
and quill pin microfluidic liquid transfer technology.
Cell culture, RNA extraction, and labeling of the cDNA
probe
All procedures involving mice were approved by the IACUC at
U.T. M.D. Anderson Cancer Center and M.I.T. E1A-expressing
mouse embryonic fibroblasts (MEFs) (wild-type, p532/2, p632/2,
p732/2,a n dp632/2;p732/2) were generated as described
previously [15] from passage 1 primary MEFs. 3610
6 E1A MEFs
were plated on each of 6–15 cm dishes. Twenty-four hours after
plating, the cells were treated with 0.34 mM doxorubicin. Twelve
hours after treatment, total RNA (150–300 mg) was extracted from
treated and untreated E1A MEFs using the RNAeasy Midi Kit
(Qiagen). For each microarray hybridization, 100 mg of total RNA
prepared from the reference or experimental cells were labeled by
incorporating Cy3- or Cy5-labeled dUTP (NEN) using oligo d(T)
(MWG) and Superscript II reverse transcriptase (Invitrogen). The
resulting probes were purified using the Qiaquick PCR purification
Kit (Qiagen) and recovered in a volume of 30 mld d H 20.
Microarray hybridization
The printed slides were rehydrated, UV cross-linked, and
blocked to reduce background using succinic anhydride (Sigma),
1-methyl 2-pyrrolidinone and sodium borate. Each slide was
incubated in 60 ml total volume of hybridization solution
containing Cy3- and Cy5-labeled target (one probe is the reference
invariant target and the other is the experimental target), 1 mgo f
Mouse Cot-1 DNA (Invitrogen), 0.1 units of poly-A40–60
(Amersham Pharmacia), and 10.1 mg of Salmon Testes DNA
(Sigma), 25% Formamide, 5X SSC, 0.1% SDS under a 22640-
mm lifterslip (Erie Scientific Company) at 42uC for 16 hours
exactly. The slide was placed in a sealed hybridization chamber
(Corning) containing two side wells with a total of 20 ml 3X SSC
for humidification in a light-sealed water bath. After exactly
16 hours of hybridization, the slide was washed in 500 ml of 1X
SSC, 0.03% SDS for 5 minutes after the lifterslips are gently
removed in the wash solution. Then, the slides were washed for
5 minutes in 0.1X SSC, 0.01% SDS followed by 0.1X SSC. Slides
were centrifuged in a speed-vac to dry. Each slide was scanned
using an arrayWoRx Auto Biochip Reader that employs white
light, polychromatic filter-wheel/CCD camera (Applied Precision)
at wavelengths corresponding to each analog’s emmision wave-
length (595 and 685 nm for Cy3 and Cy5, respectively). RNA
from each sample was hybridized to four independent cDNA
microarrays. For 2 replicates, the invariant target was labeled with
Cy3 and the experimental target was labeled with Cy5. For the
other 2 replicates for each sample, the invariant target was labeled
with Cy5 and the experimental target was labeled with Cy3. The
invariant reference target RNA used was extracted from untreated
wild type- E1A MEFs. These cells were chosen as a source of
reference target RNA because this species of RNA robustly
hybridized to a large percentage of genes, and it is relevant to the
experimental design.
Data processing
Hierarchical mapping. Microarray images imported from
the arrayWoRx scanner were filtered and annotated using the
DigitalGenome software (MolecularWare). The resulting spot
intensity data was normalized using the rank invariant method
[35]. The gene filtering process was performed using SAM [16].
SAM is a statistical technique designed for analysis of microarray
data [16] that uses repeated permutations of array data to report
the most statistically significant differentially expressed genes
between two groups of samples. Using all four microarray
replicates, SAM reports an estimate of the median false
discovery rate (FDR) for each list of differentially expressed
genes. The FDR is the percentage of genes falsely reported as
showing statistically significant differential expression. In addition,
SAM uses an algorithm based on the Student t-test to determine
the q-value of each individual gene, which is the lowest FDR at
which the gene is called significant [36]. Using the bona fide
biological target of p63, PERP, we used a cut-off FDR of 8.24% to
determine our list of significant genes. As a result, 15 genes on our
list has a q-value between 5% and 8.24% while the remaining 605
genes have a q-value less than 5%. Heatmaps were generated
using functions within the Bioconductor project [37] of the R
statistical programming language. Background subtracted and
normalized intensity values obtained from the microarray
experiment comparing the different cell populations were used.
To perform hierarchical clustering of the genes and cell samples,
Euclidean distance was used to compute dissimilarity.
Identification of p53/p63 binding sites. To identify all
potential p53-family binding sites, promoter sequences (defined as
genomic sequences within 2 kb of the transcription start site which
have previously been reported to be enriched for these sites [30])
and intron 1 were extracted for all genes regulated by each p53
family member. These promoter sequences were initially searched
for CWWG tetramers separated by a spacer of 5–8 nucleotides.
To increase the specificity and score of these predicted sites, both
strands were searched with a series of position-specific matrices for
p53 [30,31,38] and p63 [14,39] using HMMER1 v1.8 [17] with
the ‘‘local search’’ option. To rank sites predicted across multiple
matrices, all CWWG tetramer pairs were matched to corres-
ponding HHMER sites and scored using the sum of bit scores.
Quantitative Real Time PCR
Total RNA was extracted from the E1A MEFs of the genotypes
described above using the RNeasy Midi and Rnase-free Dnase kits
(Qiagen). RNA was quantified and tested for quality on the Agilent
2100 Bioanalyzer (Agilent Technologies). To generate cDNA, RNA
(2 mg) from each E1A MEF line treated with 0.34 mMd o x o r u b i c i n
was used for random hexanucleotide- primed cDNA synthesis. Each
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hexamer, 2 ml of Superscript II (Invitrogen), 0.5 mM each of all four
dNTPs, and 80 units of RNase inhibitor (Promega). Using heating
blocks, reactions were incubated at 42uC for 1 hour, 70uCf o r
15 minutes,37uCfor 20 minutes,and 95uC for 2 minutes.RNase H
(2 units) (Invitrogen) was added to each reaction following the 70uC
incubation. Afterwards, each reaction was diluted with ddH2Ot oa
final working volume of 200 ml. cDNAs (2 ml) were added to 25-ml
reaction mixtures containing 12.5 ml of 2X SYBR Green master mix
(Applied Biosystems), and 40 nm of gene-specific primers. Primers
were designed using Primer Express software (Applied Biosystems).
Assays were performed in triplicate with an ABI Prism 7000
Sequence Detector (Applied Biosystems). All data were normalized
to an internal standard (18 S ribosomal RNA; TaqMan Ribosomal
RNA Control Reagents VIC Probe: Protocol: Rev C, Applied
Biosystems) or GAPDH.
Chromatin Immunoprecipitation Assay
ChIP Assay was performed as described previously, E1A MEFs
(wild-type, p532/2, p632/2, p732/2, and p632/2;p732/2)
were untreated or treated with 0.34 mM doxorubicin for 12 hours,
which are the same conditions used for the array and real time
PCR. Cellular proteins were crosslinked to chromatin with 1%
formaldehyde. p53-DNA, p63-DNA or p73-DNA complexes were
immunoprecipitated using the following antibodies: pan-p63 (4A4,
Santa Cruz), pan-p73 (IMG-259a, Imgenex) or p53 (Ab-3,
Oncogene Research Products). Immunprecipitated complexes
were recovered by Staphylococcus A cells, treated with proteinase
K, and DNA was purified. PCR was performed for putative p53
family binding elements. Putative p53 family member binding sites
were identified by scanning 1000 bp of the 59 UTR, exon 1, intron
1, exon 2 and intron 2 for the consensus p53 binding site [31].
These sites are summarized in Table 1. Sequences for primers
used are available upon request.
Construction of luciferase reporters
To generate the pGL3-Rad51 luciferase reporter, DNA was
amplified from a BAC clone containing the Rad51 gene (RP23-
15121, CHORI BACPAC resources) using primers designed
containing the p73 binding site shown by ChIP and 59 NheI and
39 XhoI cloning restriction enzyme sites: forward primer (59-
ACTAGCTAGCAGCAGGGCGACCAACCGAC-39) and re-
verse primer (59-CCGCTCGAGTGGCCCTCCCTATCCACA-
GG-39). To construct the pGL3-BRCA2 luciferase reporter, the
DNA fragment containing the p63/p73 binding site shown by
ChIP was amplified from C57/B6 genomic DNA by PCR using
the following primers with 59 XhoI and 39 BglII cloning restriction
enzyme sites: forward primer (59-CCGCTCGAGAGAGGGAT-
CCGGCGCGTC-39) and reverse primer (59-GGAAGATCTG-
GTCTAAGCTCTGTTGCTCCTG-39. To generate the pGL3-
Mre11 luciferase reporter, DNA was amplified from a BAC clone
containing the mre11a gene (RP23-149D5, CHORI BACPAC
resources) using primers designed containing the p63 binding site
shown by ChIP and 59 XhoI and 39 BglII cloning restriction
enzyme sites: forward primer (59- CCGCTCGAGACAGAGA-
GAACCTCACCGAGAAC -39) and reverse primer (59-GGAA-
GATCTCTGTACCAGGTTCCTCTCCAAG-39). The resulting
amplified DNA fragments were gel-purified (Wizard Prep Kit,
Promega) after restriction enzyme digestion and then ligated to
pGL3-basic vector (Promega) between the respective cloning sites.
Western blot analysis
6610
5 wild-type and p632/2;p732/2 MEFs were plated on
6 cm dishes. Twelve hours after plating, the MEFs were irradiated
with 5 Gy of gamma-irradiation and then harvested at 10 min-
utes, 30 minutes, 1, 2, and 4 hours. The MEFs were lysed on ice
in lysis buffer (100 mM Tris, 100 mM NaCl, 1% Nonidet P40,
protease inhibitor cocktail (Roche)). Thirty micrograms of each
lysate was subjected to electrophoresis on a 10% SDS PAGE for
Rad51 and transferred to PVDF membrane. Rad51 was detected
using the anti-Rad51 antibody (clone 51RAD01, Neomarkers),
and BRCA2 was detected using the anti-BRCA2 antibody (clone
H-300, Santa Cruz).
Immunohistochemistry
Slides were dewaxed in xylene and rehydrated in a graded series
of ethanol following standard protocols [7]. Slides were incubated
with primary antibodies for p63 (4A4, Santa Cruz), p73 (IMG-
259A, Imgenex), Rad51 (clone 51RAD01, Neomarkers), or
BRCA2 (clone H-300), Santa Cruz). at a dilution of 1:100 for
18 hours at 4 deg C. Detection was performed using the
Vectastain kit (Vector Labs) followed by the VIP kit or DAB kit
(Vector Labs) and counterstained with methyl green (Vector Labs).
Ten normal mammary glands and ten mammary adenocarcino-
mas were stained with each antibody.
Dual-luciferase reporter assay
p632/2;p732/2, p532/2;p732/2 or p532/2;p632/2
MEFs were plated on 6-well plates (3.5610
5 cells per well).
Twelve hours after plating, the MEFs were transiently transfected
using Fugene HD (Roche) with 2.5 mg of the following Firefly
luciferase reporter plasmids (pGL3-Rad51-1, pGL3-Rad51-2,
pGL3-BRCA2) or pPERP-luc [24], 1 mg of Renilla luciferase
plasmid (transfection control), and 2.5 mg of empty vector
(pcDNA3) or plasmids encoding the p63/p73 isoforms (TAp63a,
TAp63c, DNp63c, TAp73a, TAp73b, DNp73a and DNp73b)o r
p53/ In experiments where 2 isoforms of p63 and p73 were
assayed simultaneously, 1.25 mg of each isoform was used. After
24 hr, cells were harvested and luciferase activity was measured
using the Dual-Luciferase Reporter Assay system (Promega) and a
Veritas microplate luminometer (Turner BioSystems). The relative
luciferase activity was determined by dividing the Firefly luciferase
value with the Renilla luciferase value and the fold increase in
relative luciferase activity was determined by dividing the relative
luciferase value induced by p63 and p73 isoforms with that
induced by the pcDNA3 control vector. Each experiment was
performed in triplicate.
Clonogenic survival assay
E1A MEFs or primary MEFs were plated in 6-well plates
(1610
6 cells per well) of the following genotypes (wild-type, p532/2,
p632/2,p732/2,a n dp632/2;p732/2) [15]. Twelve hours later,
MEFs were irradiated with 1, 2, and 3 Gy of gamma radiation or
0.34, 0.5, and 1 mM doxorubicin. After 12 hr, 1200 cells were plated
on 10 cm dishes. After 12 days of incubation, the cells were stained
with clonogenic reagent (0.25% of 1,9-dimethyl-methylene blue in
50% ethanol). Surviving colonies were counted, and the survival rate
was calculated as the ratio of the surviving colonies after DNA
damage treatment over the number of colonies for each genotype
before treatment. Each experiment was performed in triplicate on
three independent MEF lines for each indicated genotype.
Comet assay
Wild-type, p532/2, p632/2, p732/2,a n dp632/2;p732/2
primary and E1A MEFs were plated on 6-well dishes (1.6610
5 cells
per well). Twelve hours after plating, MEFs were irradiated with
5 Gy of gamma radiation. Cells were harvested 0,1, and 16 hours
p63 and p73 Regulate DNA Repair after DNA Damage
PLoS Genetics | www.plosgenetics.org 11 October 2009 | Volume 5 | Issue 10 | e1000680later for Comet Assay (Trevigen) according to the manufacturer’s
protocol specific for DSB detection. Briefly, cells were suspended in
PBS at a density of 3610
5 cell/mL. Twenty microliters of each cell
suspension was mixed with 200 mL of melted low melting point
agarose (LMA) and 75 mL of this mixture was placed onto the
Trevigen CometSlide for electrophoresis. Subsequent to electropho-
resis, samples were visualized with SYBR Green I and fluorescence
microscopy. Twenty pictures were taken for each sample and at least
135 cells per experiment were examined for comet tails using
CometScore software (TriTek Corporation). Three independent
MEF lines for each genotype were assayed in triplicate. Student’s t
test was used for statistical analysis.
Statistics
All experiments were performed at least in triplicate. Data are
represented as the mean 6 SEM. Statistics for qRT-PCR,
luciferase, clonogenic, and comet assays was performed using
Student’s t test for comparison between two groups. A p value of
0.05 was considered significant.
Supporting Information
Figure S1 Heatmap showing unsupervised hierarchical clustering
analysis of p53, p63,a n dp732/2 E1A MEFs after doxorubicin
treatment.Eachrowrepresentstherelativeexpressionlevelforagene
compared to an untreated isogenic MEF line. The columns represent
multiple isogenic MEF lines for each indicated genotype. Only genes
that were significantly down-regulated in at least one mutant MEF
line and not wild-type MEFs in response to doxorubicin treatment
are represented. The red color indicates high expression and the
green color indicates low expression, while black indicates no
significant change. Clustering based on Euclidean distance indicates
that p63 and p73 deficient E1A MEFs are more similar to each other
than to p532/2 E1A MEFs. The GenBank Accession Number is
shown in the right hand column.
Found at: doi:10.1371/journal.pgen.1000680.s001 (0.39 MB
PNG)
Figure S2 Genes involved in DNA repair are differentially
expressed in MEFs deficient for p63 and/or p73. Real time PCR
analysis of E1A MEFs of the following genotypes (wild-type,
p532/2, p632/2, p732/2, and p632/2;p732/2) before and
after (D) treatment with doxorubicin. The Y-axis shows the
relative mRNA levels of mre11, BRCA2, Rad51, and Rad50
before and after treatment with doxorubicin (0.34 mM) for
12 hours. GAPDH was used as an internal control. Bars represent
3 MEF lines for each genotype, each performed in triplicate. Data
represented as mean 6 SEM.
Found at: doi:10.1371/journal.pgen.1000680.s002 (2.17 MB TIF)
Table S1 Pathway analysis of p63 and p73 target genes.
Found at: doi:10.1371/journal.pgen.1000680.s003 (0.11 MB JPG)
Table S2 Identified p53/p63 binding sites for genes with
differential expression.
Found at: doi:10.1371/journal.pgen.1000680.s004 (1.10 MB
XLS)
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